Kim Y, Mills D
Food Sci Biotechnol. 2024; 33(9):2065-2080.
PMID: 39130661
PMC: 11315840.
DOI: 10.1007/s10068-024-01620-1.
Feng Y, He C, Liu C, Shao B, Wang D, Wu P
Int J Mol Sci. 2024; 25(12).
PMID: 38928150
PMC: 11204037.
DOI: 10.3390/ijms25126444.
Pyo J, Yoon T, Ahn S, Song J, Park Y, Lee S
Sci Rep. 2022; 12(1):21319.
PMID: 36494415
PMC: 9734661.
DOI: 10.1038/s41598-022-25466-x.
Andersen M
Semin Immunopathol. 2022; 45(2):253-264.
PMID: 36175673
PMC: 10335965.
DOI: 10.1007/s00281-022-00966-0.
Li J, Liu M, Zhang X, Ji L, Yang T, Zhao Y
J Cancer Res Clin Oncol. 2022; 149(8):4465-4475.
PMID: 36127483
DOI: 10.1007/s00432-022-04360-z.
Beyond Cancer: Regulation and Function of PD-L1 in Health and Immune-Related Diseases.
Beenen A, Sauerer T, Schaft N, Dorrie J
Int J Mol Sci. 2022; 23(15).
PMID: 35955729
PMC: 9369208.
DOI: 10.3390/ijms23158599.
Noncanonical PD-1/PD-L1 Axis in Relation to the Efficacy of Anti-PD Therapy.
Long Y, Yu X, Chen R, Tong Y, Gong L
Front Immunol. 2022; 13:910704.
PMID: 35663968
PMC: 9157498.
DOI: 10.3389/fimmu.2022.910704.
The generation of PD-L1 and PD-L2 in cancer cells: From nuclear chromatin reorganization to extracellular presentation.
Fan Z, Wu C, Chen M, Jiang Y, Wu Y, Mao R
Acta Pharm Sin B. 2022; 12(3):1041-1053.
PMID: 35530130
PMC: 9069407.
DOI: 10.1016/j.apsb.2021.09.010.
CMTM6 as a master regulator of PD-L1.
Yaseen M, Abuharfeil N, Darmani H
Cancer Immunol Immunother. 2022; 71(10):2325-2340.
PMID: 35294592
PMC: 10991181.
DOI: 10.1007/s00262-022-03171-y.
Bridging the Gap: Connecting the Mechanisms of Immune-Related Adverse Events and Autoimmunity Through PD-1.
Mor A, Strazza M
Front Cell Dev Biol. 2022; 9:790386.
PMID: 35047501
PMC: 8762228.
DOI: 10.3389/fcell.2021.790386.
Apoptosis, Autophagy, NETosis, Necroptosis, and Pyroptosis Mediated Programmed Cell Death as Targets for Innovative Therapy in Rheumatoid Arthritis.
Zhao J, Jiang P, Guo S, Schrodi S, He D
Front Immunol. 2022; 12:809806.
PMID: 35003139
PMC: 8739882.
DOI: 10.3389/fimmu.2021.809806.
Anti-PD1/PDL1 IgG subclass distribution in ten cancer types and anti-PD1 IgG4 as biomarker for the long time survival in NSCLC with anti-PD1 therapy.
Tan Q, Dai L, Wang Y, Liu S, Liang T, Luo R
Cancer Immunol Immunother. 2021; 71(7):1681-1691.
PMID: 34817638
PMC: 10992332.
DOI: 10.1007/s00262-021-03106-z.
Adipose-Tissue-Derived Mesenchymal Stem Cells Mediate PD-L1 Overexpression in the White Adipose Tissue of Obese Individuals, Resulting in T Cell Dysfunction.
Eljaafari A, Pestel J, Magueresse-Battistoni B, Chanon S, Watson J, Robert M
Cells. 2021; 10(10).
PMID: 34685625
PMC: 8534339.
DOI: 10.3390/cells10102645.
PD-1/PD-L1 Axis as a Potential Therapeutic Target for Multiple Sclerosis: A T Cell Perspective.
Li H, Zheng C, Han J, Zhu J, Liu S, Jin T
Front Cell Neurosci. 2021; 15:716747.
PMID: 34381337
PMC: 8350166.
DOI: 10.3389/fncel.2021.716747.
Low Infiltration of CD8+ PD-L1+ T Cells and M2 Macrophages Predicts Improved Clinical Outcomes After Immune Checkpoint Inhibitor Therapy in Non-Small Cell Lung Carcinoma.
Li L, Lu G, Liu Y, Gong L, Zheng X, Zheng H
Front Oncol. 2021; 11:658690.
PMID: 34150625
PMC: 8213070.
DOI: 10.3389/fonc.2021.658690.
The Role of Programmed Death-1 in Type 1 Diabetes.
Tucker C, Dwyer A, Fife B, Martinov T
Curr Diab Rep. 2021; 21(6):20.
PMID: 33956235
PMC: 8323125.
DOI: 10.1007/s11892-021-01384-6.
Oncolytic herpesvirus expressing PD-L1 BiTE for cancer therapy: exploiting tumor immune suppression as an opportunity for targeted immunotherapy.
Khalique H, Baugh R, Dyer A, Scott E, Frost S, Larkin S
J Immunother Cancer. 2021; 9(4).
PMID: 33820820
PMC: 8026026.
DOI: 10.1136/jitc-2020-001292.
Single-cell transcriptome analysis of the heterogeneous effects of differential expression of tumor PD-L1 on responding TCR-T cells.
Ding R, Liu S, Wang S, Chen H, Wang F, Xu Q
Theranostics. 2021; 11(10):4957-4974.
PMID: 33754038
PMC: 7978322.
DOI: 10.7150/thno.55075.
The PD-1:PD-L1 axis in Inflammatory Arthritis.
Canavan M, Floudas A, Veale D, Fearon U
BMC Rheumatol. 2021; 5(1):1.
PMID: 33423684
PMC: 7798255.
DOI: 10.1186/s41927-020-00171-2.
Lung Cancer Survival in Patients With Autoimmune Disease.
Jacob S, Rahbari K, Tegtmeyer K, Zhao J, Tran S, Helenowski I
JAMA Netw Open. 2020; 3(12):e2029917.
PMID: 33315114
PMC: 7737093.
DOI: 10.1001/jamanetworkopen.2020.29917.